AXSMAxsome Therapeutics, Inc.

$9B

FY 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$638M+65.5% YoY

Gross Profit

$591M92.6% margin

Operating Income

-$169M-26.5% margin

Net Income

-$183M-28.7% margin

EPS (Diluted)

$-3.68

Cash Flow

Operating Cash Flow

-$93M

Free Cash Flow

-$93M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$690M

Total Liabilities

$602M

Stockholders' Equity

$88M

Cash & Equivalents

$323M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$638M	$386M	+65.5%
Gross Profit	$591M	$352M	+67.7%
Operating Income	-$169M	-$281M	+39.7%
Net Income	-$183M	-$287M	+36.2%

AXSM FY 2025 Earnings — Axsome Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena